SION Stock — Sionna Therapeutics Inc.: Cash, EV, Pipeline

Share price

$5.96

Market cap

$269.5M

Cash

$211.0M

Enterprise value

$58.5M

Balance sheet

Cash	$211.0M
Debt	$0.0M
Net cash	$211.0M
Enterprise value	$58.5M
Basic shares	45.2M shares
Fully diluted shares	52.5M shares
Fully diluted market cap	$313.2M
Cash per share	$4.67

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading SION daily closes…

Loading price history…

Pipeline assets

SION-719

Phase 2 · Active Modality: small molecule NBD1 stabilizer

Target NBD1

Indications

cystic fibrosis (Stage not disclosed)

Catalysts

— None

Status note Phase 2a proof-of-concept trial (PreciSION CF) evaluating SION-719 as an add-on to standard of care (Trikafta) in CF patients; enrollment completed in April 2026. Positive topline data from two Phase 1 trials in healthy volunteers announced June 2025.

SION-451

Phase 1 · Active Modality: small molecule NBD1 stabilizer

Target NBD1

Indications

cystic fibrosis (Stage not disclosed)

Catalysts

— None

Status note Phase 1 dual-combination trial in healthy volunteers with SION-2222 and SION-109 initiated in August 2025 to inform selection of a proprietary dual combination for further development.

SION-2222

Phase 1 · Active Modality: CFTR modulator

Target CFTR

Indications

cystic fibrosis (Stage not disclosed)

Status note Complementary CFTR modulator being evaluated in dual combinations with SION-451.

SION-109

Phase 1 · Active Modality: CFTR modulator

Target CFTR

Indications

cystic fibrosis (Stage not disclosed)

Status note Complementary CFTR modulator being evaluated in dual combinations with SION-451.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	2,555,877	-974,825	2.13%	2026-08-14
Baker Bros. Advisors	400,000	no change	0.09%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

SION — Sionna Therapeutics Inc.

Balance sheet

Price history

Pipeline assets

Institutional holders